Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $39.00.

UPB has been the topic of several research analyst reports. Wall Street Zen downgraded Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday. Mizuho upgraded Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Evercore downgraded Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research report on Friday. Lifesci Capital started coverage on shares of Upstream Bio in a research note on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st.

Institutional Investors Weigh In On Upstream Bio

A number of hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in shares of Upstream Bio during the fourth quarter worth $29,000. Torren Management LLC purchased a new position in Upstream Bio in the fourth quarter valued at $30,000. Empowered Funds LLC purchased a new position in Upstream Bio in the fourth quarter valued at $45,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Upstream Bio in the fourth quarter valued at $71,000. Finally, Russell Investments Group Ltd. grew its stake in Upstream Bio by 1,963.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after purchasing an additional 2,887 shares in the last quarter.

Upstream Bio Stock Performance

NASDAQ:UPB opened at $8.67 on Friday. The stock has a market capitalization of $468.53 million, a P/E ratio of -3.25 and a beta of 2.96. The company has a 50 day moving average price of $15.93 and a 200 day moving average price of $21.35. Upstream Bio has a fifty-two week low of $5.14 and a fifty-two week high of $33.68.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.06). Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 34.90%. The firm had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.52 million. Research analysts forecast that Upstream Bio will post -4.3 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.